Apollomics Inc., a California-based biopharmaceutical company, has received a delisting notification from Nasdaq, which claims the company is now only a "public shell" due to lack of personnel and staffing uncertainties. Despite these concerns, Apollomics plans to appeal the decision, maintaining that it is still an active clinical-stage pharmaceutical company focused on developing oncology therapies. The company recently received a $4.1 million private placement and appointed a new board of directors to support its ongoing operations and strategic initiatives. Apollomics is working to address Nasdaq's concerns and retain its listing status while continuing its efforts in the oncology drug development sector.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apollomics Inc. published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.